课题基金 / 基金详情

24-dehydrocholesterol reductase(DHCR24) inhibitor suppresses HCV replication

24-dehydrocholesterol reductase(DHCR24) inhibitor suppresses HCV replication
24-脱氢胆固醇还原酶 (DHCR24) 抑制剂抑制 HCV 复制
批准号:
18390146
负责人:
KOHARA Michinori
金额:
$10.77万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

KOHARA Michinori的其他基金

相似基金

相关文献

中文摘要
翻译
丙型肝炎病毒(丙型肝炎病毒)常导致慢性肝炎、肝硬变和肝细胞癌。我们先前建立了有条件的全长丙型肝炎病毒基因表达的HepG2细胞,并观察到其在传代44天后(RzM6 44天细胞)的致瘤性增加。为了阐明是否存在表达水平随致瘤性而改变的抗原,我们建立了针对这些细胞的单抗。制备了1000多株单抗,并对其与RzM6 44天细胞的反应性进行了鉴定。几个对这些细胞具有显著不同反应性的克隆,我们首先对克隆2-152进行了鉴定,它识别了大约55kloalton(KDa)。分子(P55)。因此,我们用MALDI-TOF/MS鉴定了P55分子为24-脱氢胆固醇还原酶(24-DHO-CHO-REDUTase),它是胆固醇生物合成途径中的一个酶。U18666A是一种DHCR24的抑制剂,可以抑制丙型肝炎病毒复制子细胞的复制。我们利用人肝感染丙型肝炎病毒1a或1b的嵌合小鼠,研究了U18666A对完整丙型肝炎病毒的抗丙型肝炎病毒作用。我们给感染了丙型肝炎病毒的嵌合小鼠注射U18666A,成功地将血清和肝脏中的丙型肝炎病毒RNA水平降低到治疗前的1/10-1/100。此外,与聚乙二醇化干扰素联合治疗将丙型肝炎病毒RNA水平降低到不到对照水平的1/1000。我们强烈地认为,抑制dhr24可以减少丙型肝炎病毒的复制,因此dhr24抑制剂有可能成为治疗丙型肝炎病毒感染的一种新药。
英文摘要
Hepatitis C virus (HCV) frequently causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). We previously established the conditional full-length HCV gene expressing HepG2 cells and observed their increased tumorigenicity after 44 days passage (RzM6 44 days cells). In order to clarify the existence of antigens whose expression level has been changed according to the tumorigenicity, we established the monoclonal antibodies (MoAbs) against these cells. Over one thousand monoclonal antibodies were established, and their reactivities to RzM6 44 days cells were characterized. Several clones with significantly different reactivity to these cells, we first characterized clone 2-152, and it recognized approximately 55 killodalton (kDa.) molecule (p55). Therefore, we identified p55 molecule by MALDI-TOF/MS as 24-dehydrocholesterol reductase (DHCR24).DHCR24 is a enzyme in the cholesterol biosynthetic pathway. U18666A is an inhibitor of DHCR24 and suppresses replication of the hepatitis C virus (HCV) replicon cells. We investigated the anti-HCV effect of U18666A against intact HCV using chimeric mice with humanized liver infected with HCV genotype 1a or 1b. We administered U18666A into HCV infected chimeric mice and succeeded in reducing the HCV RNA levels in serum and liver to 1/10-1/100 of the levels prior to the 8 day treatment. Furthermore, combined treatment with pegylated interferon reduced the HCV RNA levels to less than 1/1000 of the control levels. We strongly suggest that suppression of DHCR24 reduces HCV replication, and therefore that the DHCR24 inhibitor is potentially a novel drug in the treatment of HCV infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reverse genetics system for measles virus driven by vaccinia virus Lister vaccine strain.
由痘苗病毒Lister疫苗株驱动的麻疹病毒反向遗传学系统。
DOI: --
发表时间: 2006
期刊: Journal of Virological Methods 137
影响因子: --
作者: [Tsunamasa Watanabe, Takuya Umehara, Michinori Kohara., Kitabatake M., Nakagawa S., Inoue K., Totsugawa T., Watanabe T., Mashiba T., Inoue K., Nakagawa S., Uto H., Watanabe T., Umehara T., Tanaka Y., Kaito M., Nishitsuji H., Murakami K., Suzuki T., Nakatsu Y.]
通讯作者: Nakatsu Y.
Pathogenesis of SARS-CoV infection in BALB/c mice pre-immunized with recombinant vaccinia virus expressing SARS-CoV structural proteins
表达 SARS-CoV 结构蛋白的重组牛痘病毒预免疫 BALB/c 小鼠 SARS-CoV 感染的发病机制
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Kyoko Murakami, Koji Ishii, Yousuke Ishihara, Sayaka Yoshizaki, Keiko Tanaka, Yasufumi Gotoh, Hideki Aizaki, Michinori Kohara, Hiroshi Yoshioka, Yuichi Mori, Noboru Manabe, Ikuo Shoji, Tetsutaro Sata, Ralf Bartenschlager, Yoshiharu Matsuura, Tatsuo Miyamu, Kaito M., Kaito M., Kaito M., Nakatsu Y., Murakami K., Nishitsuji H., Tanaka Y., Umehara T., Watanabe T., Uto H., 小原 道法, Tsukiyama-Kohara K., 小原 道法, Kohara M., Arai M., Nakagawa S., Nishimura T., Inoue K., Takano T., 井上 和明, 安井 文彦, 高野 貴士, 斉藤 誠, 西村 知裕, 佐藤 正明, Yasui F., Kataoka S., 安井 文彦, Yasui F.]
通讯作者: Yasui F.
免疫抑制作用のないサイクロスポリンA誘導体DEBIO-025は次世代の有望なHCV治療薬である。
DEBIO-025 是一种非免疫抑制性环孢菌素 A 衍生物,是一种有前途的下一代 HCV 治疗药物。
DOI: --
发表时间: 2006
期刊:
影响因子: --
作者: [Nishimura T., Kasama Y., Shuda M., Nakagawa S., Saito M., Kohara M., Tsukiyama-Kohara K., 井上 和明]
通讯作者: 井上 和明
C型肝炎ウイルスによる酸化ストレス応答因子の修飾
丙型肝炎病毒对氧化应激反应因子的修饰
DOI: --
发表时间: 2006
期刊:
影响因子: --
作者: [Nishimura T., Kasama Y., Shuda M., Nakagawa S., Saito M., Kohara M., Tsukiyama-Kohara K., 井上 和明, 佐藤 憲一, 渡邊 綱正, Umehara T., Umehara T., Tsukiyama-Kohara K, 小原 恭子]
通讯作者: 小原 恭子
82
    Pathology of spontaneous breast tumor in tree shrews (Tupaia belangeri chinenesis)
    Macrocycles to target influenza viral hemagglutinin as bifunctional potent broad-spectrum antiviral agent
    iHA-100 exhibited a high efficacy whether administered during the early phase or late phase of H5N1 infection
    Influenza viral hemagglutinin-targeted macrocyclic peptides as an antiviral agent
    海外基金